Interpace Biosciences Inc

IDXG.PK

$1.56

Closing

▼-2.81%

1D

▲43.98%

YTD

Market cap

$6.72M

52 week high

$3.54

52 week low

$0.62

Volume

107

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$6.72M

Analysts' Rating

-

Price Target (Mean)

-

Total Analysts

0

P/E

Operating Margin

-0.18%

Beta

0.62

Revenue Growth (Annual)

-3.86%

52 week high

$3.54

52 week low

$0.62

Div. Yield

%

EPS Annual Growth

0.00

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR v2, used in combination with ThyGeNEXT, for the diagnosis of thyroid cancer, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.